A new study published in the scientific journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat diabetic/weight-related […]
A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such as Wegovy and Ozempic. The survey was conducted by Morning Consult […]
Injectable weight loss drugs are popular right now but can be hard to get because they are in short supply or too expensive without insurance. The result is […]
A new USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with […]
The European Medicines Agency (EMA) is warning patients and healthcare professionals to beware of pre-filled pens falsely labelled as Ozempic, a diabetes medicine linked to weight loss. National […]
Data from a “real world” study indicates that treatment with the semaglutide (Ozempic/Wegovy) for type 2 diabetes significantly improves both blood sugar control and weight loss for up […]
On 27th June 2023 NHS England issued a Medicine Supply Notification (MSN/2023/061) concerning GLP-1 receptor agonists (GLP-1 RAs) used for management of type 2 diabetes. This action has […]
Deborah Evans is Superintendent Pharmacist and Clinic Director at Remedi Health, where she runs a weight management service, including the provision of semaglutide. In this series of short […]
People seeking semaglutide for weight management from a pharmacy-led service need to feel assured that the service is ethical and legal and has the best interests of the […]
Taking time to understand a patient’s weight loss goals and checking their medical history to ensure there are no underlying problems that may need onward referral are both […]
Online supply of semaglutide makes the medicine more accessible but may not provide the best support or guidance to enable people to get the best out of the […]
Wegovy and Ozempic both contain semaglutide but are authorised for different indications. They are also presented in slightly different concentrations and dose schedules, explains Deborah Evans, Superintendent Pharmacist […]
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.
